Science and Health News

The clinical trial began in 2019 and involved 3,900 volunteers.

The individual, who was treated for leukemia, is the fourth in the world and the oldest to go into long-term remission of HIV after receiving stem cells from a donor with a rare genetic mutation

A very small percentage of people with HIV-1, known as "post-treatment controllers" (PTCs), are able to control their infection after interrupting all antiretroviral therapy. Understanding the fundamental mechanisms that govern their immune response is essential in order to develop HIV-1 vaccines, novel therapeutic strategies to achieve remission, or both. A recent study investigated the humoral immune response – also known as antibody-mediated immunity – in some PTCs in whom transient episodes of viral activity were observed. The researchers have shown their humoral immune response to be both effective and robust, which could help to control the infection in the absence of treatment.

Study in mice could point toward method for clearing virus from people who would otherwise depend on medication

In the 40 years since the first published reports of the syndrome known as AIDS, more than 32 million people have died from the virus that causes it, the human immunodeficiency virus (HIV). With more than 35 million people worldwide living with HIV today and nearly two million new cases each year, HIV remains a major global epidemic.

Study uncovers stem cells’ ability to restore immunity and repair gut damage caused by HIV

The improved therapy engineers the body’s immune response against HIV rather than waiting for the virus — or parts of the virus — to induce a response.

Research from the UNC School of Medicine lab of Jenny Ting, PhD, shows that the widely used drug metformin reduces metabolism of infected T cells to suppress HIV replication.